The European Market Access Lag: 2021–2024
Pharmaceutical Technology
JUNE 9, 2025
For example, Recordati’s Cystadane (betaine) was centrally approved in 2007 but did not see its first reimbursement in Poland until 2023. In Romania, Novartis’s Atriance (nelarabine) was also centrally approved in 2007 but did not receive its first reimbursement in Romania until 2021.
Let's personalize your content